Abstract:Neoadjuvant chemoradiotherapy is the current standard of care for locally advanced rectal cancer. However, this modality is facing more and more challenges. The research progress on this issue around the world can be summarized into three aspects. The first is to increase the intensity of treatment to obtain better tumor regression, such as adding a second drug during the neoadjuvant chemoradiotherapy, prolonging the interval and receiving sufficient chemotherapy before surgery. Current research data are not sufficient to support strategies for adding drugs or receiving sufficient chemotherapy before surgery, but it may be worth looking forward to adding irinotecan during neoadjuvant chemoradiotherapy, and an appropriate extension of the interval before surgery may also be a good option. Secondly, we can reduce the intensity of treatment to improve the quality of life of patients with a non-inferior clinical outcome, such as non-surgical approach, local excision rather than total mesorectal excision and removal of preoperative radiotherapy. The data of the International Watch & Wait Database (IWWD) suggest that patients with a Watch & Wait strategy have similar long-term survival outcomes as those who have undergone surgery and have pathologic complete response, meanwhile the data are still inadequate to support using local excision instead of total mesorectal excision, or removal of preoperative radiotherapy strategies. Finally, to achieve a precise individual treatment, some potential biomarkers are investigated via genomics, metabolomics and radiomics. But so far, there is no recognized biomarker for clinical treatment in the field of neoadjuvant therapy for rectal cancer. This article summarizes the clinical research progress of locally advanced rectal cancer in recent years from the above three aspects.

Treatment of Locally Advanced/Metastatic Colorectal Cancer

Changing Patterns of Neoadjuvant Therapy for Locally Advanced Rectal Cancer: A Narrative Review

Locally Advanced Rectal Cancer: Time for Precision Therapeutics.

General Treatment for Metastatic Colorectal Cancer: from KEYNOTE 177 Study.

Evolving Standards of Care in the Management of Localized Colorectal Cancer

Treatment of Locally Recurrent Rectal Cancer

Local Therapy for Metastatic Colorectal Cancer

Treatment of Locally Recurrent Rectal Cancer: A Review

[Advances of Optimized Neoadjuvant Therapy in the Treatment of Locally Advanced Rectal Cancer].

Immunotherapy Combined with Local Therapy in the Late-Line Treatment of Repair-Proficient (pmmr)/microsatellite Stable (MSS) Metastatic Colorectal Cancer

Neoadjuvant Short- Vs. Long-Course Radiation for Locally Advanced Rectal Cancer: How to Choose

Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment

Nonoperative Management for Rectal Cancer

State-of-the-Art Management of Colorectal Cancer: Treatment Advances and Innovation

Advances in preoperative treatment of colorectal cancer

Advancing Personalized Medicine in the Treatment of Locally Advanced Rectal Cancer

Essential updates 2022–2023: Surgical and adjuvant therapies for locally advanced colorectal cancer

Local Therapy for Metastatic Colorectal Cancer: A Case-Based Review

Refractory Metastatic Colorectal Cancer: Current Challenges and Future Prospects

Treatment Options in Late-Line Colorectal Cancer: Lessons Learned from Recent Randomized Studies

An Evolving Landscape: New Therapies for Metastatic Colorectal Cancer